FILGRASTIM
Pleomorphic Xanthoastrocytoma, Anaplastic
St. Jude Children's Research Hospitalprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Pleomorphic Xanthoastrocytoma, Anaplastic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
gsk1120212 National Cancer Institute (NCI) | Phase 4 | BB |
Dabrafenib National Cancer Institute (NCI) | Phase 4 | BB |
(+)-VINCRISTINE Novartis Pharmaceuticals | Phase 2 | B |
Carboplatin Novartis Pharmaceuticals | Phase 2 | B |
Binimetinib Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | CCC |
View all 9 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →